https://www.biopharmawatch.com/news/RGNX/regenxbio-investor-event-surabgene-lomparvovec-wet-amd BiopharmaWatch en 2026-10-12T11:05:00.000Z REGENXBIO to Host Investor Event Highlighting Surabgene Lomparvovec (Sura-vec) in Wet AMD on October 20 https://www.biopharmawatch.com/news/PODD/insulet-announces-omnipod-discover-release BiopharmaWatch en 2026-10-12T11:00:00.000Z Insulet Announces Omnipod Discover Now Available in U.S. https://www.biopharmawatch.com/news/TRAX/first-tracks-biotherapeutics-anb033-celiac-disease-results BiopharmaWatch en 2026-10-12T11:00:00.000Z First Tracks Biotherapeutics Announces Positive Top-Line Results for ANB033 in Gluten-Challenge Study in Celiac Disease https://www.biopharmawatch.com/news/VANI/vivani-medical-investor-conferences-october-2026 BiopharmaWatch en 2026-10-12T11:00:00.000Z Vivani Medical Announces Participation in Upcoming Investor Conferences https://www.biopharmawatch.com/news/ZBIO/zenas-biopharma-obexelimab-igg4-related-disease-data BiopharmaWatch en 2026-10-12T11:00:00.000Z Zenas BioPharma Announces the Presentation of New Obexelimab Data in IgG4-Related Disease at the 6th International Symposium on IgG4-Related Disease https://www.biopharmawatch.com/news/HRMY/harmony-biosciences-ceo-transition-growth BiopharmaWatch en 2026-10-12T11:00:00.000Z Harmony Biosciences Announces Planned CEO Transition to Support Next Phase of Growth https://www.biopharmawatch.com/news/IRIX/iridex-micropulse-technology-glaucoma-study BiopharmaWatch en 2026-10-12T11:00:00.000Z Iridex Announces the Publication of Two-Year Independent Study Supporting Benefits of MicroPulse® Technology for Early to Advanced Glaucoma https://www.biopharmawatch.com/news/FATE/fate-therapeutics-jamie-harrell-appointment BiopharmaWatch en 2026-10-12T11:00:00.000Z Fate Therapeutics Appoints Jamie Harrell as Senior Vice President, Market Development & Commercial Operations to Lead the Commercialization of CAR T-cell Therapies https://www.biopharmawatch.com/news/BMY/bms-positive-results-phase-3-action-1-ryz101 BiopharmaWatch en 2026-10-12T10:55:00.000Z Bristol Myers Squibb Announces Positive Topline Results from the Interim Analysis of Phase 3 ACTION-1 for RYZ101, RayzeBio’s Radiopharmaceutical Therapy, in Patients with GEP-NETs https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-synchronocity-trial-results BiopharmaWatch en 2026-10-12T10:55:00.000Z ANI Pharmaceuticals Announces Positive Phase 4 Open-Label, Single-Arm SYNCHRONICITY Clinical Trial Results Presented as Late Breaking Oral Presentation at the American Academy of Ophthalmology 2026 Annual Meeting https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-phase-3-aloft-ipf-trial-admilparant BiopharmaWatch en 2026-10-12T10:50:00.000Z Bristol Myers Squibb Announces Phase 3 ALOFT-IPF Trial Evaluating Admilparant in Adults with Idiopathic Pulmonary Fibrosis Met Primary Endpoint https://www.biopharmawatch.com/news/BLCO/bausch-lomb-appoints-thomas-appio-ceo BiopharmaWatch en 2026-10-12T10:45:00.000Z Bausch + Lomb and Bausch Health Announce Appointment of Thomas J. Appio as Interim Bausch + Lomb CEO, Expect to Raise Full-Year 2026 Guidance https://www.biopharmawatch.com/news/TFX/enrollment-completed-biomag-ll-clinical-study-tfx BiopharmaWatch en 2026-10-12T10:30:00.000Z Enrollment Completed in BIOMAG™-LL Clinical Study Evaluating Longer Lengths for Freesolve™ Resorbable Magnesium Scaffold https://www.biopharmawatch.com/news/NVO/novo-nordisk-s-share-repurchase-programme-20261012 BiopharmaWatch en 2026-10-12T10:29:00.000Z Novo Nordisk A/S - share repurchase programme https://www.biopharmawatch.com/news/MNOV/medicinova-ceo-shareholder-update-phase-2-trial BiopharmaWatch en 2026-10-12T10:00:00.000Z MediciNova CEO Provides Shareholder Update https://www.biopharmawatch.com/news/BMY/global-patient-week-bms-ehtiwaa-small-wins BiopharmaWatch en 2026-10-12T08:10:00.000Z On the 12th Edition of Global Patient Week Bristol Myers Squibb and Saudi Schizophrenia Association 'Ehtiwaa' Collaborate to Support People Living with Schizophrenia Through the 'Small Wins' Initiative https://www.biopharmawatch.com/blog/biotech-catalysts-to-watch-week-of-2026-10-12 BiopharmaWatch en 2026-10-12T07:15:20.465Z IGALMI PDUFA for Bipolar Disorders: Biotech Catalysts Oct 12, 2026 https://www.biopharmawatch.com/news/MEDS/humana-medicaid-coverage-chemofx-assay-gynecologic-cancers BiopharmaWatch en 2026-10-12T06:00:00.000Z DataMEDS SI Announces Helomics Receives Medicaid Coverage Policy For Chemofx(R) Assay In Gynecologic Cancers https://www.biopharmawatch.com/news/MIRM/mirum-investor-call-phase-3-expand-study-livmarli BiopharmaWatch en 2026-10-11T21:00:00.000Z Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases https://www.biopharmawatch.com/news/TRAX/first-tracks-biotherapeutics-anb033-phase-1b-trial-data BiopharmaWatch en 2026-10-11T20:00:00.000Z First Tracks Biotherapeutics to Announce Top-Line Data from Cohort 1 of Phase 1b Trial of ANB033, a CD122 antagonist, in Celiac Disease on Oct. 12, 2026 https://www.biopharmawatch.com/news/BBIO/acoramidis-improves-outcomes-vs-tafamidis-attr-cm BiopharmaWatch en 2026-10-11T18:30:00.000Z Acoramidis Associated with Significantly Improved Clinical Outcomes Versus Tafamidis in ATTR-CM in an Independent, Real-World Study of U.S. Electronic Health Records https://www.biopharmawatch.com/news/FRNM/freenome-new-validation-data-crc-screening-test-acg-2026 BiopharmaWatch en 2026-10-11T17:00:00.000Z Freenome to Present New Validation Data for Next-Generation CRC Screening Test in Late-Breaking Oral Presentation at ACG 2026 https://www.biopharmawatch.com/news/BBIO/encaleret-phase-3-calibrate-trial-results BiopharmaWatch en 2026-10-11T15:42:00.000Z Encaleret Increased Bone Turnover and Improved Participant-Reported Symptoms in the Phase 3 CALIBRATE Trial in ADH1 https://www.biopharmawatch.com/news/MRK/merck-presents-one-year-results-pivotal-phase-2b-3-brunello BiopharmaWatch en 2026-10-10T22:10:00.000Z Merck Presents One-Year Results from the Pivotal Phase 2b/3 BRUNELLO Study Evaluating Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, in Adults with Diabetic Macular Edema at AAO 2026 https://www.biopharmawatch.com/news/MRK/merck-brunello-study-results-remigromig-dme BiopharmaWatch en 2026-10-10T22:10:00.000Z Merck Presents One-Year Results from the Pivotal Phase 2b/3 BRUNELLO Study Evaluating Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, in Adults with Diabetic Macular Edema at AAO 2026 https://www.biopharmawatch.com/news/LBRX/lb-pharmaceuticals-preclinical-data-lb-102-ecnp-congress BiopharmaWatch en 2026-10-10T12:00:00.000Z LB Pharmaceuticals Presents New Preclinical Data Supporting LB-102’s Bimodal Mechanism of Action and Highlights Ongoing Late-Stage Clinical Development Programs at the 39th ECNP Congress https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-presentation-breakthrough-t1d-congress-2026 BiopharmaWatch en 2026-10-10T12:00:00.000Z vTv Therapeutics Announces Oral Presentation at Breakthrough T1D Clinical and Research Congress 2026